Reumuth Mary 4
4 · Kala Pharmaceuticals, Inc. · Filed Jun 23, 2023
Insider Transaction Report
Form 4
Reumuth Mary
CHIEF FINANCIAL OFFICER
Transactions
- Award
Common Stock
2023-06-22+36,144→ 62,763 total - Award
Stock Option (right to buy)
2023-06-22+48,192→ 48,192 totalExercise: $14.56Exp: 2033-06-21→ Common Stock (48,192 underlying)
Footnotes (3)
- [F1]Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on June 22, 2024, as to 1/3 of the shares underlying the RSUs on June 22, 2025 and as to the final 1/3 of shares underlying the RSUs on June 22, 2026.
- [F2]Includes 60,556 unvested RSUs.
- [F3]This option was granted on June 22, 2023 and vests over four years beginning on the vesting commencement date of June 22, 2023, with 25% of the shares underlying the option vesting on June 22, 2024, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter.